Cipla Ltd. — Regulatory Filings 2021

Nov 2, 2021

3[rd] November, 2021

(1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA EQ

• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG

Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Update on intimations dated 13[th] November, 2018 and 8[th] February, 2019 on acquisition agreement entered between InvaGen Pharmaceuticals Inc. and Avenue Therapeutics Inc.

Dear Sir/Madam,

In reference to the above mentioned intimations, Company’s wholly owned step down subsidiary, InvaGen Pharmaceuticals Inc. (“InvaGen”), USA had entered into a Stock Purchase and Merger Agreement (“the SPMA”) for acquisition of Avenue Therapeutics Inc. (“Avenue”), a company focused on the development and commercialization of intravenous (IV) Tramadol.

Since the second stage closing could not be completed as per the agreed timelines, in the terms of the SPMA, InvaGen has received a notice of termination from Avenue. InvaGen is evaluating the notice for any further steps that it may be required to take in this regard.

The existing shareholding of InvaGen in Avenue shall continue.

This is for your information and record.

Thankyou

Yours Faithfully,

For Cipla Limited

RAJENDRA Digitally signed by RAJENDRA KUMAR KUMAR CHOPRA CHOPRA Date: 2021.11.03 00:00:12 +05'30' Rajendra Chopra Company Secretary

Prepared by: Mandar Kurghode